Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat Ratings reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback